Author

M.-J. Navarro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

A. C. Walls· 3 shared J. E. Bowen· 3 shared D. Veesler· 2 shared M. A. Tortorici· 2 shared M. McCallum· 2 shared W. C. Van Voorhis· 2 shared A. Blackstone· 1 shared A. Chen· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. C. Walls

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses

A. C. Walls, K. R. Sprouse, A. Joshi, J. E. Bowen, N. Franko, M.-J. Navarro, C. Stewart, M. McCallum, E. A. Goecker, E. J. Degli-Angeli, J. Logue, A. Greninger, H. Chu, D. Veesler

The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.

bioRxiv · Dec 8, 2021 · PreprintImmunology

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

bioRxiv · Mar 31, 2021 · PreprintImmunology

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

bioRxiv · Mar 15, 2021Immunology